KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics, Inc. (PVLA) EPS (Weighted Average and Diluted) (2020 - 2022)

Palvella Therapeutics (PVLA) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with $0.12 as the latest value for Q4 2024.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 99.41% to $0.12 in Q4 2024 year-over-year; TTM through Dec 2024 was -$7.83, a 170.92% decrease, with the full-year FY2024 number at -$7.83, down 460.83% from a year prior.
  • EPS (Weighted Average and Diluted) was $0.12 for Q4 2024 at Palvella Therapeutics, up from -$3.94 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $20.5 in Q4 2023 to a low of -$9.25 in Q3 2023.
  • A 5-year average of $0.28 and a median of -$0.19 in 2021 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 200.85% in 2021, then surged 1898.39% in 2023.
  • Palvella Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.26 in 2020, then soared by 46.15% to -$0.14 in 2021, then dropped by 0.0% to -$0.14 in 2022, then skyrocketed by 14742.86% to $20.5 in 2023, then tumbled by 99.41% to $0.12 in 2024.
  • Per Business Quant, the three most recent readings for PVLA's EPS (Weighted Average and Diluted) are $0.12 (Q4 2024), -$3.94 (Q3 2024), and -$2.47 (Q2 2024).